Gilead (GILD) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $86.3M

Market Cap: $168.5BFounded: 1987Employees: 11,000+HQ: Foster City, United States

Sector Ranking#41 in Small Molecule Drugs #2 in Oncology (General)

Overview

Gilead Sciences is a fully integrated biopharmaceutical giant with a mission to create a healthier world by advancing transformative therapies for serious diseases. It achieved historic success by pioneering curative treatments for hepatitis C and life-sustaining regimens for HIV, establishing a dominant virology franchise. The company's current strategy is to expand its leadership into oncology and inflammation through internal R&D and strategic acquisitions, while maintaining its commitment to health equity and global access.

VirologyOncologyInflammation

Technology Platform

A multi-modal approach combining deep small-molecule expertise with leading cell therapy (via Kite) and antibody-drug conjugate (ADC) platforms, enabling targeted intervention across virology, oncology, and inflammation.

Funding History

1

Total raised:$86.3M

IPO$86.3MUndisclosedJan 22, 1992

FDA Approved Drugs

29

YEZTUGONDAJun 18, 2025

LIVDELZINDAAug 14, 2024

Opportunities

Gilead's primary growth opportunities lie in expanding its oncology footprint through earlier-line approvals for Trodelvy and Yescarta, successfully launching its TIGIT combination in lung cancer, and building a new franchise in inflammatory diseases.

The long-acting HIV portfolio and pursuit of functional cures for hepatitis B offer sustained growth in virology.

Risk Factors

Key risks include clinical trial failures in late-stage oncology/inflammation programs, intense competition eroding market share for new launches, and the long-term patent expiry of core HIV assets threatening the company's largest revenue stream.

Competitive Landscape

Gilead faces formidable competition: in HIV from ViiV Healthcare; in cell therapy from Bristol Myers Squibb; in ADCs from AstraZeneca/Daiichi Sankyo; and in inflammation from AbbVie and J&J. Its scale, financial resources, and multi-platform strategy are its main competitive tools.